Product Description: Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA)[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Sifuentes Giraldo WA, et al. New targets in systemic lupus (part 2/2). Reumatol Clin. 2012 Sep-Oct;8(5):263-9. /[2]Liu Yunjie, et al. Research progress on the pathogenesis and drug targeting therapy of B lymphocyte stimulator-induced rheumatoid arthritis. 2011;22(33):3152-3154. /[3]La Cava A. Targeting B cells with biologics in systemic lupus erythematosus. Expert Opin Biol Ther. 2010 Nov;10(11):1555-61. /[4]Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002 Oct;17(4):515-24.
CAS Number: 869881-54-9
Molecular Weight: N/A
Compound Purity: 97.66
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: ADC Antibody
English
Deutsch
